Immune Pharmaceuticals (NASDAQ: IMNP) is one of 115 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Immune Pharmaceuticals to related companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, profitability, dividends and risk.
Insider & Institutional Ownership
3.4% of Immune Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.7% of Immune Pharmaceuticals shares are held by insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Immune Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Immune Pharmaceuticals||N/A||-$32.66 million||-0.12|
|Immune Pharmaceuticals Competitors||$7.99 billion||$1.06 billion||150.28|
Immune Pharmaceuticals’ rivals have higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and recommmendations for Immune Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Immune Pharmaceuticals Competitors||867||3810||6898||192||2.55|
As a group, “Pharmaceuticals” companies have a potential upside of 25.25%. Given Immune Pharmaceuticals’ rivals higher possible upside, analysts plainly believe Immune Pharmaceuticals has less favorable growth aspects than its rivals.
This table compares Immune Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Immune Pharmaceuticals Competitors||-2,418.96%||-59.81%||-8.20%|
Volatility & Risk
Immune Pharmaceuticals has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals’ rivals have a beta of 32.13, meaning that their average stock price is 3,113% more volatile than the S&P 500.
Immune Pharmaceuticals rivals beat Immune Pharmaceuticals on 8 of the 9 factors compared.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.